Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-121062
Filing Date
2024-11-05
Accepted
2024-11-05 06:57:32
Documents
77
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q apls-20240930.htm   iXBRL 10-Q 2246344
2 EX-31.1 apls-ex31_1.htm EX-31.1 16700
3 EX-31.2 apls-ex31_2.htm EX-31.2 15924
4 EX-32.1 apls-ex32_1.htm EX-32.1 8725
5 EX-32.2 apls-ex32_2.htm EX-32.2 8808
  Complete submission text file 0000950170-24-121062.txt   9437230

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apls-20240930.xsd EX-101.SCH 1553762
79 EXTRACTED XBRL INSTANCE DOCUMENT apls-20240930_htm.xml XML 1601219
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38276 | Film No.: 241425568
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)